A proposed national strategy for tuberculosis vaccine development.
The global tuberculosis epidemic causes approximately 5% of deaths worldwide. Despite recent concerted and largely successful tuberculosis control efforts, the incidence of tuberculosis in the United States remains 74-fold higher than the stated elimination goal of <1 case per million population by the year 2010. Current bacille Calmette-Guérin vaccines, although efficacious in preventing extrapulmonary tuberculosis in young children, have shown widely variable efficacy in preventing adult pulmonary tuberculosis, confound skin test screening, and are not recommended for use in the United States. The Advisory Council for Elimination of Tuberculosis recently stated that tuberculosis would not be eliminated from the United States without a more effective vaccine. Recent scientific advances have created unprecedented opportunity for tuberculosis vaccine development. Therefore, members of the broad tuberculosis research and control communities have recently created and proposed a national strategy, or blueprint, for tuberculosis vaccine development, which is presented here.
Ginsberg
A M
AM
Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-7630, USA. ag73i@nih.gov.
D000328:Adult; D001500:BCG Vaccine / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D006291:Health Policy; D006801:Humans; D007391:International Cooperation; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D012106:Research; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States / Q000453:epidemiology
D001500:BCG Vaccine; D001428:Bacterial Vaccines